Marilyn Glassberg
Chair, Department of Medicine Medicine Loyola University Chicago Stritch School of Medicine
Seminars
Wednesday 30th September 2026
Panel Discussion: A Year in Review: Charting the Evolving IPF Landscape & Implications for Drug Development
9:30 am
The past year has been transformative for IPF, with new therapies, emerging mechanisms, and evolving patient management strategies reshaping the landscape. This panel will provide a strategic, forward-looking overview of how the field has progressed and what the next 12-18 months may hold. Panellists will discuss the expanding pathophysiology of IPF, emerging classifications of therapies, and implications for patient care, clinical development strategy, and communication with stakeholders.
Key Discussion Points:
- How newly approved therapies and emerging candidates are expected to influence IPF treatment and clinical and research priorities in the next 12–18 months.
- Exploring the practical impact of emerging terminology, anti-fibrotic, anti-inflammatory, de-differentiation, fibrolysis, and how these distinctions may shape patient and clinician preferences
- Approaches for ordering, timing, and combining therapies in a multi-drug era, balancing efficacy, safety, and operational feasibility.
- Identifying opportunities, challenges, and areas for collaboration to ensure trials and programs remain aligned with evolving clinical practice
Tuesday 29th September 2026
Identifying Patients at Risk: Detecting Early Interstitial Lung Disease & Predicting Progression to Enable Earlier Intervention
12:00 pm
- Examining how interstitial lung abnormalities detected through screening imaging may represent the earliest stages of fibrotic lung disease and identifying the clinical features that predict progression to clinically significant ILD
- Exploring emerging circulating biomarkers, genetic risk factors, and proteomic signatures associated with disease severity, mortality risk, and likelihood of progression
- Understanding how early identification of high-risk patients could enable earlier therapeutic intervention and more efficient recruitment into ILD clinical trials
